You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

persistent cervical cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cervical Cancer Trial (Sacituzumab Govitecan)

Not yet recruiting
  • Cervical Cancer
  • Sacituzumab Govitecan
  • (no location specified)
Apr 18, 2023

Cervical Cancer Trial in Wuhan (Cadonilimab, Anlotinib)

Recruiting
  • Cervical Cancer
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Apr 5, 2023

Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer Trial in Mobile (Cabozantinib 40 MG oral once a day,

Terminated
  • Cervical Cancer
  • +3 more
  • Cabozantinib 40 MG oral once a day
  • Pembrolizumab 200 mg IV every 3 weeks
  • Mobile, Alabama
    University of South Alabama Mitchell Cancer Institute
Jun 3, 2022

Persistent, Recurrent, or Metastatic Cervical Cancer Trial in Shanghai (GLS-010, Placebo, paclitaxel)

Not yet recruiting
  • Persistent, Recurrent, or Metastatic Cervical Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Hospital
Apr 4, 2023

Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)

Not yet recruiting
  • Cervical Cancer
  • TQB2868 injection
  • +4 more
  • Chongqing, Chongqing, China
  • +1 more
Aug 17, 2023

Stage IVB Cervical Cancer, Recurrent Cervical Cancer, Persistent Cervical Cancer Trial in Guangzhou (Camrelizumab, Apatinib,

Recruiting
  • Stage IVB Cervical Cancer
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 25, 2021

METASTATIC CERVICAL CANCER Trial (QL1706, Placebo)

Recruiting
  • METASTATIC CERVICAL CANCER
  • Chongqing, Chongqing, China
  • +2 more
Nov 24, 2022

Cervical Cancer Trial in Miami (Pembrolizumab, Paclitaxel, Cisplatin)

Recruiting
  • Cervical Cancer
  • Miami, Florida
    University of Miami
Oct 1, 2022

Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)

Not yet recruiting
  • Uterine Cervical Neoplasms
  • +5 more
  • (no location specified)
Apr 9, 2023

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

Cervical Cancer Trial in Hangzhou (Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin)

Recruiting
  • Cervical Cancer
  • Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Jul 12, 2022

Human Papilloma Virus Infection, Human Papilloma Virus Integration, Cervical Intraepithelial Neoplasia Trial in Wuhan

Not yet recruiting
  • Human Papilloma Virus Infection
  • +4 more
  • diagnostic cervical conization
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Aug 19, 2022

Cervical Cancer Trial in Hong Kong (Avelumab, Axitinib)

Recruiting
  • Cervical Cancer
  • Hong Kong, Hong Kong
    The University of Hong Kong
Feb 23, 2022

Cervical Cancer Trial in Hangzhou, Hefei, Shanghai (AK104, paclitaxel, carboplatin)

Recruiting
  • Cervical Cancer
  • AK104
  • +5 more
  • Hangzhou, China
  • +4 more
Apr 26, 2022

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • +9 more
  • Radiotherapy for targeted lesions and PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Cervical Cancer Trial in Shanghai (Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection)

Recruiting
  • Cervical Cancer
  • Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection
  • Shanghai, Shanghai, China
  • +1 more
Jul 26, 2022

Targeted Therapy, Chemo, Recurrent Cervical Carcinoma Trial in Beijing (Donafenib combined with paclitaxel and platinum ± PD-1

Recruiting
  • Targeted Therapy
  • +6 more
  • Donafenib combined with paclitaxel and platinum ± PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Chemotherapy plus apatinib)

Completed
  • Recurrent Cervical Carcinoma
  • +5 more
  • Chemotherapy plus apatinib
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting
  • Recurrent Cervical Carcinoma
  • +9 more
  • Tislelizumab plus radiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1

Completed
  • Recurrent Cervical Carcinoma
  • +4 more
  • A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,

Recruiting
  • Recurrent Cervical Carcinoma
  • +5 more
  • Anti-PD-1 antibody camrelizumab
  • Albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Cervical Cancer Trial in Guangzhou (SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel +

Recruiting
  • Cervical Cancer
  • SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 13, 2022

Cervical Cancer Trial in Chongqing (niraparib combined with brivanib, niraparib combined with toripalimab)

Recruiting
  • Cervical Cancer
  • niraparib combined with brivanib
  • niraparib combined with toripalimab
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
May 19, 2021

Cervical Cancer Trial (AK105 and anlotinib)

Not yet recruiting
  • Cervical Cancer
  • AK105 and anlotinib
  • (no location specified)
Nov 29, 2021

Recurrent Cervical Carcinoma, Metastatic Cervical Cancer Trial in Guangzhou, Guanzhou (SHR-1210, Apatinib)

Active, not recruiting
  • Recurrent Cervical Carcinoma
  • Metastatic Cervical Cancer
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2021